Preparation method and application of phage targeting ExPEC

Through phage treatment targeting ExPEC, the problem of irreversible liver damage and inflammatory response in alcohol-related liver disease is solved, and the reduction of liver enzymes and inflammatory genes and the reduction of liver lipid deposition and inflammation is achieved, providing a new effective treatment method.

CN117987379BActive Publication Date: 2024-12-06XIEHE HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI & TECH UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410194655.0
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-02-21
Publication Date
2024-12-06
Estimated Expiration
2044-02-21

AI Technical Summary

Technical Problem

The prior art lacks effective methods for treating alcohol-related liver diseases, especially difficult to reverse liver damage and inflammatory responses, and liver transplantation cannot be widely implemented due to high prices and lack of donors.

Method used

Prepare phages targeting ExPEC, proliferate, isolate and purify through the mixing ratio of host bacteria and phage filtrate, and are used to treat or prevent alcohol-related liver disease. Use phages to specifically attack ExPEC in the intestine to alleviate liver steatosis and inflammatory damage in the liver. .

Benefits of technology

Phages targeting ExPEC can accurately attack ExPEC in the intestine without affecting other intestinal bacteria, significantly reducing liver enzyme levels, inflammation-related gene expression, liver lipid deposition and inflammatory cell infiltration, providing a new Effective treatment of alcohol-related liver disease.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117987379B_ABST
    Figure CN117987379B_ABST
Patent Text Reader

Abstract

The present invention discloses a preparation method and application of a bacteriophage targeting ExPEC; the bacteriophage targeting ExPEC is prepared by using a logarithmic phase bacterial solution of extraintestinal pathogenic Escherichia coli from pigs as a host bacterium, and is mixed with a phage filtrate and a culture medium in proportion, and then cultured, separated and purified; the bacteriophage targeting ExPEC can accurately target ExPEC in the intestine without affecting other intestinal flora, thereby reducing its aggravating effect on alcohol-induced liver fatty degeneration and inflammatory damage, and phage-targeted ExPEC therapy is expected to become one of the new effective treatments for alcohol-related liver disease.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine technology, and in particular relates to a preparation method and application of a bacteriophage targeting ExPEC. Background Art

[0002] Alcohol-related liver disease refers to a series of liver lesions caused by excessive or long-term drinking, including alcoholic fatty liver, alcoholic hepatitis, alcoholic cirrhosis and alcoholic liver cancer. According to surveys, the proportion of drinking population and the prevalence of alcohol-related liver disease are on the rise worldwide. In 2019, about 25% of deaths from cirrhosis worldwide were related to alcohol, and the annual incidence of hepatocellular carcinoma in patients with alcohol-related cirrhosis ranged from 0.9% to 5.6%. Obviously, alcohol-related liver disease has imposed a huge burden on socioeconomics and global health. However, so far, there are no approved effective treatments for alcohol-related liver disease other than abstinence and liver transplantation. Abstinence and liver transplantation cannot become widely and effectively implemented treatment options in clinical practice due to the difficulty of long-term adherence and lack of donors. Therefore, it is urgent to find new treatments for alcohol-related liver disease.

[0003] 1. Etiology and pathogenesis of alcohol-related liver disease

[0004] The etiology and pathogenesis of alcohol-related liver disease are relatively complex. The high-risk factors for alcohol-related liver disease found by domestic and foreign studies include: the type of alcoholic beverages, the amount of alcohol consumed, the number of years of drinking, nutritional status, genetic susceptibility and race. To date, the pathological mechanism of alcohol-related liver disease has not been fully elucidated, but it is generally believed to be related to the following three points. First, alcohol and its active metabolite acetaldehyde can directly cause liver toxicity; second, liver damage can further induce the release of damage-associated molecular patterns, thereby recruiting innate and adaptive immune cells, causing a series of immune inflammatory responses and aggravating liver damage; finally, alcohol intake can affect the abundance and composition of intestinal flora, destroy the intestinal barrier, and cause the intestinal flora and its metabolites to translocate to the liver, causing immune responses and liver damage.

[0005] Treatment of alcohol-related liver disease

[0006] The treatment principles of alcohol-related liver disease include abstinence and nutritional support, reducing the severity of alcoholic liver disease, improving existing secondary malnutrition and symptomatic treatment of alcoholic cirrhosis and its complications. Abstinence is the most important measure for the treatment of alcohol-related liver disease, and withdrawal syndrome should be prevented and treated during the abstinence process. It is worth noting that patients with alcohol-related liver disease may still progress to alcoholic liver fibrosis and cirrhosis after abstinence. For patients with advanced alcoholic cirrhosis, simple abstinence cannot effectively reverse liver damage and liver transplantation is required. Of course, liver transplantation can also be considered for patients with alcoholic hepatitis who do not respond to drug treatment. Liver transplantation is difficult to become a widely implemented treatment method in clinical practice due to its high price and lack of donors. Therefore, there is an urgent need to develop more effective and universal treatment drugs and programs for alcohol-related liver disease. In fact, many clinical studies have focused on this and developed some potential treatment drugs for alcohol-related liver disease. Based on the existing literature, the drugs that may have therapeutic potential are summarized as follows:

[0007] 1. Alleviate liver cell damage

[0008] There is increasing evidence that hepatocellular injury, at least in part caused by ethanol-induced oxidative stress and innate immune responses, plays a crucial role in the progression of alcohol-related liver disease. Therefore, protecting hepatocytes from damage is viewed as a potential therapeutic strategy. S-adenosylmethionine can restore mitochondrial glutathione and improve steatosis in rodents, and thus may be a potential therapeutic option for alcohol-related liver disease. Granulocyte colony-stimulating factor (G-CSF) is a potent growth factor that has been proposed to promote hepatocyte regeneration in severe alcoholic hepatitis. A meta-analysis showed that G-CSF was associated with a more than 70% reduction in 90-day mortality in patients with alcoholic hepatitis. In addition, F-652, an agonist of the anti-inflammatory cytokine IL-22, has been shown in a phase 2 clinical trial to reduce inflammatory markers and promote liver regeneration in patients with alcoholic hepatitis.

[0009] (II) Reducing inflammatory response

[0010] Chronic inflammation is a key factor in the development of alcohol-related liver disease, suggesting that regulating the inflammatory response is a promising therapeutic strategy to improve alcohol-related liver disease. Glucocorticoids (such as prednisolone) are currently commonly used as first-line anti-inflammatory drugs for patients with severe alcoholic hepatitis; however, prednisolone is ineffective in most patients and increases the risk of bacterial and fungal infections. In a clinical study in the UK, after 28 days of treatment of alcoholic hepatitis patients with IL-1β antibodies, the results of liver biopsies of these patients showed that their livers had undergone histological improvements.

[0011] Targeted microbial therapy

[0012] In recent years, with the increasing understanding of the effects of ethanol on intestinal pathophysiology, the intestinal microbiota has become one of the main targets for developing treatments for alcohol-related liver disease. In animal experiments, probiotics help restore the diversity of intestinal microorganisms in mice and improve liver damage and intestinal barrier damage in mice. In a multicenter RCT, the probiotic group significantly reduced TNF-α and LPS in patients with alcoholic hepatitis compared with the placebo group. In addition, clinical studies have shown that even patients with severe alcoholic hepatitis can change their intestinal microbiota and improve their liver damage after receiving microbiota from healthy donors without complications. In addition, in a recent study, Duan et al. found that cytolysin-secreting E. faecalis strains are an important factor in aggravating hepatocellular damage and death in patients with severe alcoholism. Using humanized mice colonized with bacteria collected from the feces of AH patients, the researchers found that certain phages specifically target E. faecalis with cytolytic effects, reduce cytolysin in the liver, and eliminate ethanol-induced liver disease. This phage therapy provides a way to precisely edit the intestinal microbiota, but more people need to participate in clinical trials to verify these results.

[0013] 3. Bacteriophage

[0014] Bacteriophages are viruses that invade bacterial cells. The invasion of these viruses causes bacterial cells to lyse, disrupting bacterial metabolism and causing the bacteria to self-destruct. Phage therapy is a treatment method for treating pathogenic bacterial infections by lysing bacteria with phages. In recent years, scientists have made progress in using phage therapy to treat bacteria such as Mycobacterium, Klebsiella pneumoniae, Escherichia coli, influenza viruses, and diseases such as alcoholic liver disease and inflammatory bowel disease associated with intestinal bacteria.

[0015] Phage therapy has the following advantages: (1) Bacterial host specificity: Each phage attacks only a very limited number of bacteria and is almost specific to one type of bacteria. Therefore, they can target specific pathogenic bacteria without affecting the normal bacterial flora in the host. (2) Easy to grow and purify: Similar to antibiotics, bacteria can also develop resistance to phages, but developing new phages is much simpler than developing new antibiotics. It only takes a few weeks to obtain new phages, while it takes many years to obtain new antibiotics. (3) Strong penetration: They can reach all sites of bacterial infection, while the concentration of antibiotics will drop rapidly below the infected surface, so phages have special advantages when used locally. (4) Reproducibility: The number of phages will increase when the target bacterial population spreads, so small doses can be administered. (5) Non-toxicity: phages only invade bacteria and not human cells. (6) Self-limiting: Once the target bacterial population is eliminated, the number of phages will drop sharply. In general, phages have become an effective choice for fighting bacterial infections due to their many advantages. Summary of the invention

[0016] The purpose of the present invention is to provide a method for preparing a phage targeting ExPEC, so as to obtain a phage targeting ExPEC for preparing a drug for treating or preventing alcohol-related liver disease, thereby opening up a new treatment method for alcohol-related liver disease.

[0017] In view of this, the scheme of the present invention is as follows:

[0018] In one aspect of the present invention, a method for preparing a bacteriophage targeting ExPEC is provided, wherein the bacteriophage is obtained by mixing a host bacterium, a bacteriophage filtrate and a culture medium in proportion, and then proliferating, culturing, separating and purifying the bacterium; the host bacterium is a logarithmic phase bacterial solution of extraintestinal pathogenic Escherichia coli from pigs.

[0019] Furthermore, the phage filtrate is obtained by centrifuging environmental sewage to obtain the supernatant and microfiltration to remove bacteria. The environmental sewage includes but is not limited to aquaculture sewage, domestic sewage, food processing sewage, river water and other sewage that is conducive to the reproduction of bacteriophages; aquaculture sewage such as poultry breeding sewage, livestock farm sewage, domestic sewage such as vegetable market sewage, living area sewage, etc.

[0020] Furthermore, the porcine extraintestinal pathogenic Escherichia coli is obtained by inoculating and culturing the Escherichia coli PCN033 strain.

[0021] Furthermore, the volume ratio of the host bacteria, phage filtrate and culture medium is 1:1:2; and / or the culture medium is TSB culture medium.

[0022] Furthermore, the separation step uses a double-layer plate method to separate phages; and / or the purification step uses a dot-blot method to purify phages.

[0023] The second aspect of the present invention provides a bacteriophage obtained by the preparation method described in the first aspect.

[0024] The third aspect of the present invention provides the use of the bacteriophage described in the second aspect in the preparation of a drug for treating or preventing alcohol-related liver disease.

[0025] Furthermore, the drug also includes one or more pharmaceutically or physiologically acceptable carriers, and / or excipients, and / or diluents.

[0026] Furthermore, the drug reduces the content of liver enzymes in serum, and / or reduces the expression of genes related to liver inflammation, and / or alleviates lipid deposition and inflammatory cell infiltration in the liver.

[0027] Preferably, the liver enzymes include ALT and AST; and the liver inflammation-related genes include IL-1β, Cxcl1 and Cxcl2.

[0028] Compared with the prior art, the beneficial effects of the present invention include but are not limited to:

[0029] 1. The present invention provides a method for preparing the phage targeting ExPEC, the materials are readily available, the process is simple and convenient, and it is suitable for promotion.

[0030] 2. The ExPEC-targeted phage obtained by the present invention can accurately target ExPEC in the intestine without affecting other intestinal flora, thereby reducing its aggravating effect on alcohol-induced liver fatty degeneration and inflammatory damage. Therefore, phage therapy is expected to become one of the new effective treatments for alcohol-related liver disease. BRIEF DESCRIPTION OF THE DRAWINGS

[0031] In order to more clearly illustrate the technical solutions in the embodiments of the present invention, the following briefly introduces the drawings required for use in the description of the embodiments. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without creative work.

[0032] Figure 1 Schematic diagram of phage lysis plaques in Example 1.

[0033] Figure 2 This is the TEM electron microscope image of the bacteriophage in Example 2.

[0034] Figure 3 The figure shows the effects of different treatments in Example 3 on liver enzyme levels in mouse serum.

[0035] Figure 4 This is a graph showing the effects of different treatments in Example 3 on the expression of genes related to liver inflammation in mice.

[0036] Figure 5 This is a graph showing the effects of different treatments in Example 3 on fatty degeneration and inflammation in mouse liver tissue. DETAILED DESCRIPTION

[0037] In order to make the purpose, technical scheme and beneficial technical effects of the present invention clearer, the technical scheme of the present invention is further described in detail in conjunction with the embodiments. It should be understood that the specific implementation methods described in this specification are only for explaining the present invention, not for limiting the present invention.

[0038] Example 1 Preparation of bacteriophage

[0039] A method for preparing a bacteriophage targeting intestinal ExPEC comprises the following steps:

[0040] (1) Sample treatment: The collected environmental sewage was centrifuged at 8000 rpm for 15 min, and the supernatant was sterilized by filtering through a 0.22 μm microporous filter to obtain a filtrate containing bacteriophages.

[0041] (2) Preparation of host bacteria: A single colony of Escherichia coli PCN033 was selected and inoculated into 1 ml of LB broth, and cultured at 220 r / min and 37°C for 24 h to obtain a host bacteria suspension for later use.

[0042] (3) Phage proliferation: The host bacteria PCN033 bacterial solution was transferred to TSB medium at a ratio of 1:100, and cultured at 220 r / min and 37°C for 1.5-3 h to the logarithmic phase. The host bacteria, phage filtrate, and TSB medium were added to a sterilized conical flask at a ratio of 1:1:2 (volume ratio), mixed, and cultured at 220 r / min and 37°C for 2-3 h to enrich the phage.

[0043] (4) Phage Isolation: After the above phage multiplication liquid was allowed to stand at 4°C for 2 h, 20 mL was taken and centrifuged at 7000 rpm at 4°C for 10 min. The supernatant was filtered through a 0.22 μm microporous filter to obtain the phage stock solution for phage isolation.

[0044] (5) Use the double-layer plate method to isolate phages. Take 300 μL of the bacterial suspension of the host bacteria in a sterile 10 mL EP tube, add 1 mL of the phage stock solution, and then add the melted semi-solid to 8 mL. Quickly pour it into the prepared plate with TSA culture medium as the bottom layer. Tilt and rotate the plate to make it evenly distributed. After the agar solidifies, invert and culture it at 37°C overnight to observe the results. If there are phages in the stock solution, they will form silkworm-like transparent spots on the upper agar plate, forming a sharp contrast with the yellow-white misty bacterial lawn.

[0045] (6) Phage purification: Phage purification was performed using the dot plaque method. Use a sterile 200μL pipette tip to pick up a plaque with a relatively uniform shape and size, inoculate it into 3ml of PBS, shake it and let it stand at 4℃ for 2h, take the supernatant and sterilize it through a 0.22μm microporous filter. Dilute the filtrate with PBS for later use. Take 300μL of the host bacterial suspension in a sterile 10mL EP tube, add the melted semi-solid agar medium to 8mL, and quickly pour it into the prepared plate with TSA medium as the bottom layer. Tilt and rotate the plate to make it evenly distributed. After the agar solidifies, take 10μL of the phage filtrate according to the dilution and dot it on the plate. After drying, invert and culture it at 37℃ overnight. Use a sterile 10μL pipette tip to pick up a single plaque and inoculate it into 1mL of PBS. Shake it and let it stand at 4℃ for 2h, take the supernatant and sterilize it through a 0.22μm microporous filter, and mark it as F1. Repeat this step 3-5 times, and the size and morphology of the plaques observed each time remain uniform. Figure 1 As shown, purified phage was obtained.

[0046] Example 2 Characterization of phage targeting ExPEC

[0047] Take 10 μL of phage proliferation solution (10 9 PFU / mL) was dripped onto the copper grid, left to stand for 15 minutes, excess liquid was removed with filter paper, 10 μL of 2% phosphotungstic acid was dripped for 5-10 minutes, and naturally dried, and the morphological characteristics of the bacteriophage were observed under a transmission electron microscope. Transmission electron microscopy (TEM) images are shown below. Figure 2 As shown, the electron micrograph shows that the head diameter of ph033 is about 92nm and the tail is about 107nm long. Phylogenetic analysis based on the nucleotide sequence of the major capsid protein of the phage showed that ph033 is a member of the Tequatrovirus genus of the Myoviridae family.

[0048] Example 3 Effect of phage targeting ExPEC

[0049] 1. Purpose: To construct an internationally recognized alcoholic liver model (NIAAA model), give different treatments (oral administration of PBS, ExPEC, ExPEC + phage targeting ExPEC), detect liver steatosis and inflammation-related indicators, and determine whether ExPEC can aggravate alcohol-induced liver damage. If so, further determine whether phage targeting ExPEC can reverse the aggravating effect of ExPEC on the pathological progression of alcohol-related liver disease.

[0050] 2. Experimental methods: C57 mice (8 weeks old) were used. After one week of adaptation, they were first given Lieber-DeCarli control liquid feed for 5 days. Then, the "alcohol model group" was given 5% (vol / vol) Lieber-DeCarli alcohol liquid feed for 10 days, and the "control group" was given a control feed with the same calorie content as the alcohol group. According to the different treatments of each group from the 6th to the 15th day, the "control group" and the "alcohol model group" were further divided into the "PBS group" (each mouse was gavaged with 100ul PBS on the 6th, 9th, 12th and 15th day of modeling), the "ExPEC group" (each mouse was gavaged with 100ul ExPEC on the 6th, 9th, 12th and 15th day of modeling, and the number of ExPEC was 10^9 CFU / mouse) and the "ExPEC+phage group" (each mouse was gavaged with 100ul ExPEC on the 6th, 9th, 12th and 15th day of modeling, and the number of ExPEC was 10^9 CFU / mouse, and on the 15th day, 1 hour after the mice were gavaged with ExPEC, each mouse was gavaged with 100ul phage, the number was 10^11 PFU / mouse). Finally, on the 16th day, the mice in the alcohol model group were gavaged with a large amount of alcohol (40% vol / vol, 5g / Kg). Three hours later, each mouse in the "PBS group" was gavaged with 100ul PBS, and each mouse in the "ExPEC group" and "ExPEC+phage group" was gavaged with 100ul ExPEC, with a quantity of 10^9 CFU / mouse. One hour later, each mouse in the "PBS group" and "ExPEC group" was gavaged with 100ul PBS, and each mouse in the "ExPEC+phage group" was gavaged with 100ul phage, with a quantity of 10^11 PFU / mouse. Nine hours after the alcohol gavage, the mice were anesthetized, and blood, liver and other specimens were taken for relevant tests.

[0051] 3. Experimental results:

[0052] 1) ExPEC can further aggravate the increase of liver enzymes (alanine aminotransferase ALT, aspartate aminotransferase AST, which are positively correlated with the degree of liver damage) caused by alcohol, while bacteriophages can reverse this aggravating effect.

[0053] Figure 3 The liver enzyme levels in the serum of each group, Figure A: the level of serum alanine aminotransferase ALT in each group of mice; Figure B: the level of aspartate aminotransferase AST in each group of mice. The differences among the three groups were analyzed using the One-Way Anova test. If the data did not meet the normality or variance homogeneity, the Kruskal-Wallis test was used *: p < 0.05, **p < 0.01. Figure 3It is not difficult to see that the liver enzyme level of the "alcohol model group" is significantly higher than that of the "control group", indicating that the alcoholic liver model was successfully established. In addition, in the "alcohol model group", compared with the "PBS group", the liver enzyme level of the "ExPEC group" was significantly increased; and compared with the "ExPEC group", the liver enzyme level of the "ExPEC+phage group" decreased. This shows from the biochemical level that ExPEC can aggravate alcohol-induced liver damage, while phage can reverse this aggravating effect of ExPEC.

[0054] 2) ExPEC can further aggravate the upregulation of inflammation-related genes (IL-1β, Cxcl1, Cxcl2) induced by alcohol, while phage can reverse this aggravating effect.

[0055] Figure 4 The expression levels of inflammation-related genes (IL-1β, Cxcl1 and Cxcl2) in the liver of each group are common tissue inflammatory factors, and the higher the expression level, the more severe the inflammatory damage). Figure A: expression of IL-1β in the liver; Figure B: expression of Cxcl1 in the liver; Figure C: expression of Cxcl2 in the liver. The differences among the three groups were analyzed using the One-Way Anova test. If the data did not conform to normality and homogeneity of variance, the Kruskal-Wallis test was used. *: p<0.05, **p<0.01. Figure 4 It is not difficult to see that the levels of IL-1β, Cxcl1 and Cxcl2 in the "alcohol model group" were significantly higher than those in the "control group", indicating that the alcoholic liver model was successfully established. In addition, in the "alcohol model group", compared with the "PBS group", the levels of IL-1β, Cxcl1 and Cxcl2 in the "ExPEC group" were significantly increased; and compared with the "ExPEC group", the levels of IL-1β, Cxcl1 and Cxcl2 in the "ExPEC+phage group" decreased. This shows from the transcriptome level that ExPEC can aggravate alcohol-induced liver inflammation, while phage can reverse this aggravating effect of ExPEC.

[0056] 3) ExPEC can further aggravate alcohol-induced liver steatosis and inflammation, while phages can reverse this aggravating effect.

[0057] Figure 5The results of HE staining of the pathological conditions of liver tissues in each group are shown in the figure at 200 times magnification. Liver HE staining determines liver fatty degeneration and hepatitis through the distribution and composition of vacuoles of varying sizes in the cytoplasm of hepatocytes and inflammatory cells. Compared with the "control group", the "alcohol model group" had a significant increase in fat vacuoles, and inflammatory cell infiltration, mainly lymphocytes, appeared, indicating that the alcoholic liver model was successfully established. In addition, in the "alcohol model group", compared with the "PBS group", the volume of fat vacuoles in the "ExPEC group" was significantly increased, the number was significantly increased, and the inflammatory cell infiltration was more obvious; compared with the "ExPEC group", the volume of fat vacuoles in the "ExPEC+phage group" was significantly reduced, the number was significantly reduced, and the inflammatory cell infiltration was also reduced. This shows from the histological level that ExPEC can aggravate alcohol-induced liver fatty degeneration and inflammation, while phage can reverse this aggravating effect of ExPEC.

[0058] 4. Experimental conclusion: The phage targeting ExPEC can significantly reverse the aggravating effect of ExPEC on alcohol-related liver disease at multiple levels: at the biochemical level, the phage of the present invention can significantly reduce the levels of serum biochemical indicators reflecting liver damage (ALT and AST); at the transcriptional level, it can significantly reduce the expression of liver inflammation-related genes (IL-1β, Cxcl1 and Cxcl2); at the tissue level, it can reduce lipid deposition and inflammatory cell infiltration in the liver.

[0059] Although the present invention is disclosed as above, the protection scope of the present invention is not limited thereto. Those skilled in the art may make various changes and modifications without departing from the spirit and scope of the present invention, and these changes and modifications will fall within the protection scope of the present invention.

Claims

1. Use of bacteriophage in the preparation of drugs for treating or preventing alcohol-related liver disease; the bacteriophage is obtained by mixing host bacteria, phage filtrate and culture medium in proportion, then proliferating, culturing, isolating and purifying; the host bacteria is a logarithmic phase bacterial liquid of extraintestinal pathogenic Escherichia coli from pigs, and the extraintestinal pathogenic Escherichia coli from pigs is obtained by inoculating and culturing Escherichia coli PCN033 strain; the phage filtrate is obtained by centrifuging environmental sewage to obtain the supernatant and microfiltration to remove bacteria; the alcohol-related liver disease is caused or aggravated by ExPEC.

2. The use according to claim 1, characterized in that: The volume ratio of the host bacteria, phage filtrate and culture medium is 1:1:2; and / or the culture medium is TSB culture medium.

3. The use according to claim 1, characterized in that: The separation step uses a double-layer plate method to separate phages; and / or the purification step uses a spot plaque method to purify phages.

4. The use according to claim 1, characterized in that: The medicament further comprises one or more pharmaceutically or physiologically acceptable carriers, and / or excipients, and / or diluents.

5. The use according to claim 1, characterized in that: The drug reduces the content of liver enzymes in serum, and / or reduces the expression of genes related to liver inflammation, and / or alleviates lipid deposition and inflammatory cell infiltration in the liver.

6. The use according to claim 5, characterized in that: The liver enzymes include ALT and AST; the liver inflammation-related genes include IL-1β, Cxcl1 and Cxcl2.